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Incidence of switching to second-line antiretroviral therapy 
and associated factors in children with HIV: an international 
cohort collaboration
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration*
Summary
Background Estimates of incidence of switching to second-line antiretroviral therapy (ART) among children with HIV 
are necessary to inform the need for paediatric second-line formulations. We aimed to quantify the cumulative 
incidence of switching to second-line ART among children in an international cohort collaboration.
Methods In this international cohort collaboration study, we pooled individual patient-level data for children younger 
than 18 years who initiated ART (two or more nucleoside reverse-transcriptase inhibitors [NRTI] plus a non-NRTI 
[NNRTI] or boosted protease inhibitor) between 1993 and 2015 from 12 observational cohort networks in the 
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration. Patients 
who were reported to be horizontally infected with HIV and those who were enrolled in trials of treatment monitoring, 
switching, or interruption strategies were excluded. Switch to second-line ART was defined as change of one or more 
NRTI plus either change in drug class (NNRTI to protease inhibitor or vice versa) or protease inhibitor change, 
change from single to dual protease inhibitor, or addition of a new drug class. We used cumulative incidence curves 
to assess time to switching, and multivariable proportional hazards models to explore patient-level and cohort-level 
factors associated with switching, with death and loss to follow-up as competing risks.
Findings At the data cutoff of Sept 16, 2015, 182 747 children with HIV were included in the CIPHER dataset, of whom 
93 351 were eligible, with 83 984 (90·0%) from sub-Saharan Africa. At ART initiation, the median patient age was 
3·9 years (IQR 1·6–6·9) and 82 885 (88·8%) patients initiated NNRTI-based and 10 466 (11·2%) initiated protease 
inhibitor-based regimens. Median duration of follow-up after ART initiation was 26 months (IQR 9–52). 3883 (4·2%) 
patients switched to second-line ART after a median of 35 months (IQR 20–57) of ART. The cumulative incidence of 
switching at 3 years was 3·1% (95% CI 3·0–3·2), but this estimate varied widely depending on the cohort monitoring 
strategy, from 6·8% (6·5–7·2) in settings with routine monitoring of CD4 (CD4% or CD4 count) and viral load to 
0·8% (0·6–1·0) in settings with clinical only monitoring. In multivariable analyses, patient-level factors associated 
with an increased likelihood of switching were male sex, older age at ART initiation, and initial NNRTI-based regimen 
(p<0·0001). Cohort-level factors that increased the likelihood of switching were higher-income country (p=0·0017) 
and routine or targeted monitoring of CD4 and viral load (p<0·0001), which was associated with a 166% increase in 
likelihood of switching compared with CD4 only monitoring (subdistributional hazard ratio 2·66, 95% CI 2·22–3·19).
Interpretation Our global paediatric analysis found wide variations in the incidence of switching to second-line ART 
across monitoring strategies. These findings suggest the scale-up of viral load monitoring would probably increase 
demand for paediatric second-line ART formulations.
Funding International AIDS Society-CIPHER, UK Medical Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In 2017, an estimated 1·8 million children (younger than 
15 years) were living with HIV worldwide, of whom 
52% had access to antiretroviral therapy (ART).1 
A concerted effort will be needed to achieve the ambitious 
UNAIDS 90-90-90 goals to end AIDS by 2020 among 
children: ensuring that 90% of children living with HIV 
are diagnosed, 90% of those diagnosed are on ART, 
and 90% of those on ART attain and maintain viral 
suppression.2 Children and adolescents have persistently 
lagged behind adults in their progress towards the first 
two 90% targets,3 leading to increased efforts to expand 
access to HIV diagnosis and ART for children across a 
variety of clinical settings in several countries.4 As more 
children receive ART and treatment programmes mature, 
development of strategies to meet the third 90% target of 
sustained viral suppression will be the long-term challenge. 
Achievement of this goal requires a comprehensive 
understanding of the durability of first-line ART regimens 
and patterns of switching to second-line ART across geo-
graphical regions and different country-income settings to 
ensure future treatment needs are met.5
The short-term effectiveness of ART in children is 
undisputed, with high survival, immune and growth 
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recovery, and the proportion of patients with a suppressed 
viral load at 12 months after initiation of ART ranging 
from 70% to 95%.6–8 Comparatively less data are available 
on the durability of first-line ART and the use of second-
line treatment in children. The PENPACT trial,9 which 
comprised patients from predominately high-income 
countries, reported that 71% (188 of 266) of children 
remained on their first-line regimen 5 years after starting 
ART, compared with 95% or more of children in the 
CHER8 and ARROW7 trials that comprised children from 
Africa. Observational cohorts have reported wide 
variations in the probability of switching to second-line 
ART after treatment failure, with the definition of 
treatment failure varying between studies. One large 
South African observational cohort10 reported that 19% of 
children (Kaplan-Meier estimate, 95% CI 18–21) had 
virological failure 3 years after initiation of ART. Among 
the 252 children with 1 year or more of follow-up after 
virological failure, 38% (95% CI 32–45) switched to 
second-line ART. In a west African cohort,11 322 (12%) of 
2676 children with HIV had clinical-immunological 
failure after 24 months of ART, of whom 21 (7%) switched 
to second-line ART. Other cohort studies in Asia12 and 
Europe13 have reported a 17–23% probability of children 
switching to second-line ART by 5 years after initiation of 
ART. Comparison across these studies is difficult because 
of the heterogeneity of patients’ characteristics, initial 
ART regimens, monitoring strategies, and the varying 
definitions of treatment failure and switching.
We aimed to provide the first global estimates of 
the incidence of switching to second-line ART among 
children with HIV using a uniform definition of switching, 
and to assess associated factors (ie, patient-level and 
cohort-level factors). This analysis is a key step in 
understanding the use of second-line regimens globally 
and across programmes that operate under various 
strategies for treatment monitoring and guide lines for 
switching to second-line ART.
Methods
Study design and population
In this international cohort collaboration study, we 
pooled data from the Collaborative Initiative for 
Paediatric HIV Education and Research (CIPHER) 
network. CIPHER is a global network of observational 
paediatric HIV cohorts. The collaboration includes 
12 international networks: Baylor International Pediatric 
AIDS Initiative (BIPAI); European Pregnancy and 
Paediatric HIV Cohort Collaboration (EPPICC); the 
International Epidemiology Databases to Evaluate AIDS 
(IeDEA) Consortium, comprising IeDEA Asia-Pacific, 
IeDEA Central Africa, IeDEA East Africa, IeDEA 
Southern Africa, IeDEA West Africa, and Caribbean, 
Central and South America network (CCASAnet); 
International Maternal Pediatric Adolescent AIDS 
Clinical Trials (IMPAACT) 219C and P1074; Médecins 
Sans Frontières (MSF); Optimal Models (ICAP at 
Columbia University); and Pediatric HIV/AIDS Cohort 
Study (PHACS). The network covers 52 countries and 
most networks comprised multiple cohorts and each 
cohort included data from one or more clinics (primary 
care clinic, primary community clinic, or hospital). 
We pooled individual participant-level data from the 
CIPHER dataset for patients younger than 10 years at 
enrolment (a proxy for perinatal HIV infection), younger 
than 18 years at initiation of a standard combination ART 
Research in context
Evidence before this study
We searched PubMed for studies published in English from 
database inception to Nov 16, 2017, that assessed the probability 
of switching to second-line antiretroviral therapy (ART) in 
children with HIV across geographical regions and under 
different monitoring strategies using the search terms 
“child”, “children”, OR “adolescent”; “HIV”, “antiretroviral 
therapy”, “switch”, AND “second-line”. We identified several 
clinical trials and several cohort studies that reported on the 
probability of switching that used various different definitions of 
switching. Few studies estimated the incidence of switching to 
second-line ART in children across several countries with 
different strategies of treatment monitoring. To our knowledge, 
no published global-level analysis of switching to second-line 
ART among children exists that uses a uniform definition of 
switching.
Added value of this study
This study provides the first global estimates of the incidence 
of switching to second-line ART, using individual patient-level 
data for over 93 000 children across 52 countries. We found a 
low cumulative incidence of switching of 3·1% by 3 years after 
initiation of ART globally, but with significant variations across 
geographical regions and by treatment monitoring strategies. 
Compared with CD4 (CD4% or CD4 cell count) or clinical only 
monitoring, children in settings with routine or targeted 
monitoring of viral load were twice as likely to switch to 
second-line ART.
Implications of all the available evidence
As HIV treatment programmes mature, understanding 
patterns in the use of second-line ART is crucial to ensure 
future needs of paediatric treatment are met. The wide 
variations in the incidence of switching to second-line ART 
across regions and monitoring strategies highlight the need 
to assess the effect of low rates of switching and prolonged 
treatment failure before switching on clinical outcomes in 
children and the potential implications of expanding access to 
viral load testing on future use of second-line ART in resource-
limited settings.
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regimen (ie, at least three antiretroviral drugs, including 
at least two nucleoside reverse-transcriptase inhibitors 
[NRTIs] plus either a non-NRTI [NNRTI] or a ritonavir-
boosted protease inhibitor) between Jan 1, 1993, and 
Sept 1, 2015, and with 1 day or more of follow-up after 
initiation of ART. Patients who were reported to be 
horizontally infected and those enrolled in clinical trials 
of treatment monitoring, switching, or interruption 
strategies were excluded.
Individual patient-level data were sent to the University 
of Cape Town (Cape Town, South Africa) for data cleaning 
and data management using a standardised protocol 
based on the HIV Cohorts Data Exchange Protocol. The 
dataset was then sent to the University College London 
(London, UK) for analysis.
All participating networks received local ethics 
approvals to transfer anonymised data for this study. The 
pooling of data at the University of Cape Town was 
approved by the University of Cape Town Health Research 
Ethics Committee (UCT HREC [reference 264/2014]).
Outcomes 
The main study outcome was cumulative incidence of all-
cause switching to second-line ART from first-line ART 
for any reason (hereafter referred to as switching). 
Switching was defined as change of one or more NRTI 
plus either change in drug class (NNRTI to protease 
inhibitor or vice versa) or protease inhibitor change, 
change from single to dual protease inhibitor, or addition 
of a new drug class. With this definition we endeavoured 
to capture major treatment changes because of treatment 
failure or major toxic side-effects of drugs and allow for 
comparisons with previous analyses of switching in 
children that used similar approaches.12,13
Statistical analysis
We explored cohort-level and patient-level potential 
predictors for switching. We generated cohort-level 
factors, which were geographical region, treatment 
monitoring strategy, and country-income group. The 
geographical regions with eligible data were categorised 
as Europe, the USA, Asia, Latin America (ie, the Caribbean, 
and Central and South America), southern Africa, and the 
rest of sub-Saharan Africa. Southern Africa was defined 
as Botswana and South Africa and was considered 
separate from the rest of sub-Saharan Africa because 
lopinavir-based regimens were introduced in 2010 as 
first-line ART for children younger than 3 years in 
Botswana and South Africa and are not part of the 
standardised first-line regimen in the rest of sub-Saharan 
Africa, and Botswana and South Africa also had early roll-
out of routine viral load monitoring in 2007–08,14,15 unlike 
the rest of sub-Saharan Africa.16
Strategies for treatment monitoring were assigned at 
the cohort level according to the presence and frequency 
of measurements of CD4 (CD4% or CD4 count) and 
viral load. Cohorts were classified as having routine 
monitoring of CD4 or viral load if more than 60% of 
children had one or more measurement of CD4 or viral 
load after initiation of ART and the median time 
between consecutive measurements was fewer than 
60 weeks. Cohorts were classified as having targeted 
monitoring of CD4 or viral load if 5–60% of children 
had one or more measurements of CD4 or viral load 
after initiation of ART, or if more than 60% of children 
had one or more measurements but consecutive 
measures were more than 60 weeks apart. On the basis 
of these definitions, cohorts were classified into four 
groups: routine monitoring of CD4 and viral load, 
routine monitoring of CD4 and targeted monitoring of 
viral load, routine monitoring of CD4 only (<5% of 
children with viral load measurements), or clinical 
monitoring only (ie, targeted monitoring of CD4 only, or 
<5% of participants have measurements of CD4 and 
viral load). Country-income groups were assigned by 
use of the World Bank classification17 (high-income and 
upper-middle-income, lower-middle-income, or low-
income economies) at the median year of ART initiation 
in the cohort.
We investigated the following patient-level independent 
variables measured at ART initiation: sex, age (<3, 3–5, 
6–9, and ≥10 years), known previous AIDS diagnosis 
(WHO stage 3–4 or US Centres for Disease Control and 
Prevention stage C; yes or no), initial ART regimen 
(protease inhibitor or NNRTI based), and calendar year 
(≤2004, 2005–2007, 2008–2010, and ≥2011). We also 
collected data on bodyweight and CD4% or CD4 count at 
initiation of ART where available.
We calculated the weight-for-age Z scores relative to the 
1990 British Growth Reference values in Stata18 (≤–2, 
>–2 to 0, and >0) and immunodeficiency for age with the 
WHO standard definition19 based on CD4% or CD4 cell 
count. Conventionally, CD4% is reported for children 
younger than 5 years and CD4 count is reported for 
children aged 5 years and older. No immunodeficiency is 
defined as CD4% over 35% for those younger than 
12 months, over 30% for those aged 12–35 months, or 
over 25% for those aged 36–59 months, and a CD4 count 
of over 500 cells per μL for those aged 5 years or older; 
mild immunodeficiency is defined as CD4% of 30–35% 
for those younger than 12 months, 25–30% for those 
aged 12–35 months, or 20–25% for those aged 
36–59 months, and a CD4 count of 350–499 cells per μL 
for those aged 5 years or older; advanced immuno-
deficiency is defined as CD4% of 25–29% for those aged 
12 months or younger, 20–24% for those aged 
12–35 months, or 15–19% for those aged 36–59 months, 
and a CD4 count of 200–349 cells per μL for those aged 
5 years or older; and severe immunodeficiency is defined 
as CD4% less than 25% for those younger than 
12 months, less than 20% for those aged 12–35 months, 
or less than 15% for those aged 35–59 months, and a CD4 
count of less than 200 cells per μL for those aged 5 years 
or older. 
For the HIV Cohorts Data 
Exchange Protocol website see 
http://www.hicdep.org
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We used descriptive statistics to illustrate the patient-
level and cohort-level characteristics at ART initiation. 
Patients were censored at the earliest of the following: 
switching to second-line ART, death, last visit, or 
21st birthday. We summarised the cumulative incidence 
of switching allowing for the competing risks of death 
and loss to follow-up.20 Cumulative incidence of switching 
at 3 years after initiation of ART was stratified by 
geographical region, initial ART regimen, and cohort 
monitoring strategy.
Patients were considered as lost to follow-up if they had 
no visit data for 1 year or more before our study data 
inclusion cutoff (Sept 16, 2015), except for cohorts in the 
EPPICC, PHACS, and IMPAACT networks, for which a 
cutoff of 2 years or more was used because data collection 
for these cohorts is done annually and to account for 
time lags in reporting. We administratively censored 
follow-up of children at the date of last clinic visit. 
Additionally, we administratively censored patients who 
transferred to a different clinical site not part of a 
participating cohort during their follow-up or if they were 
transferred to adult care.
We summarised the independent associations between 
cumulative incidence of switching and patient char- 
acteristics at initiation of ART and cohort characteristics 
by subdistribution hazard ratios calculated using 
multivariable competing-risks proportional hazards 
re gression.21 
Additionally, the number of children in southern 
Africa younger than 3 years at the time of initiating 
a lopinavir-based regimen who switched to an 
NNRTI-based second-line regimen aged 3 years or 
older is reported and their viral load at time of switching 
summarised. 
We did two sensitivity analyses. First, to assess the 
potential association between low weight-for-age Z score, 
immunosuppression at initiation of ART, and likelihood 
of switching. We repeated the regression models using 
patient-level data from a subset of cohorts in which more 
than 60% of children had bodyweight and CD4 measure-
ments at ART initiation, and did the multivariable 
analysis with and without weight-for-age Z score and 
immunodeficiency for age. 
In the second sensitivity analysis, we repeated all 
analyses redefining switching to second-line ART by 
removing the requirement for a simultaneous change of 
one or more NRTI when changing across drug class 
(NNRTI to protease inhibitor or vice versa) or within the 
protease inhibitor drug class.
We did all analyses using Stata version 14.2.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
At the time of data cutoff, Sept 16, 2015, the CIPHER 
dataset comprised patient-level data on 182 747 children 
living with HIV, of whom 93 351 (51%) met our inclusion 
criteria (appendix p 20). 12 networks covering 52 countries 
in the CIPHER database had eligible children, and most 
children were in the rest of sub-Saharan Africa (71%), 
with 19·1% in southern Africa, 6·6% in Asia, and the 
remaining 3·5% in Europe, Latin America, and the USA 
(figure 1). The calendar year of ART initiation ranged 
Figure 1: Geographical distribution of children with HIV included in study
USA
192 (0·2%)
Latin America
926 (1·0%)
Europe
2142 (2·3%)
Asia
6107 (6·6%)
Southern Africa
17 857 (19·1%)
Rest of sub-Saharan Africa
66 127 (70·8%)
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USA 
(n=192)
Latin America 
(n=926)
Europe 
(n=2142)
Asia 
(n=6107)
Southern Africa 
(n=17 857)
Rest of sub-Saharan 
Africa (n=66 127)
Total 
(n=93 351)
Sex
Male 89 (46·4%) 441 (47·6%) 1016 (47·4%) 3213 (52·6%) 9070 (50·8%) 33 236 (50·3%) 47 065 (50·4%)
Female 103 (53·7%) 485 (52·4%) 1126 (52·6%) 2894 (47·4%) 8784 (49·2%) 32 859 (49·7%) 46 251 (49·6%)
Missing data 0 0 0 0 3 (<0·1%) 32 (<0·1%) 35 (<0·1%)
Age, years
Median 0·7 (0·2–3·4) 4·2 (1·6–7·3) 3·2 (0·7–7·0) 4·5 (2·3–7·0) 3·6 (1·1–6·8) 3·8 (1·7–6·9) 3·9 (1·6–6·9)
<3 138 (71·9%) 362 (39·1%) 1028 (48·0%) 1927 (31·6%) 8082 (45·3%) 27 856 (42·1%) 39 393 (42·2%)
3–5 34 (17·7%) 242 (26·1%) 447 (20·9%) 2068 (33·9%) 4127 (23·1%) 16 876 (25·5%) 23 794 (25·5%)
6–9 20 (10·4%) 244 (26·4%) 450 (21·0%) 1910 (31·3%) 4934 (27·6%) 19 042 (28·8%) 26 600 (28·5%)
≥10 0 78 (8·4%) 217 (10·1%) 202 (3·3%) 714 (4·0%) 2353 (3·6%) 3564 (3·8%)
CD4% (<5 years)*
n (%) 92 (57·1%) 323 (61·5%) 995 (75·0%) 2208 (65·9%) 7315 (67·6%) 14 643 (37·0%) 25 576 (45·9%)
Median 32 (24–38) 19 (13–28) 23 (16–33) 15 (8–21) 17 (11–24) 16 (11–21) 16 (11–23)
CD4 cell count (≥5 years)*
n (%) 21 (67·7%) 391 (97·5%) 718 (88·1%) 2381 (86·5%) 4753 (67·5%) 16 262 (61·2%) 24 526 (65·2%)
Median 409 (218–631) 335 (165–568) 330 (204–525) 195 (59–332) 308 (147–537) 306 (162–522) 297 (148–507)
Immunodeficiency for age† 113 (58·9%) 714 (77·1%) 1718 (80·2%) 4693 (76·9%) 12 202 (68·3%) 31 452 (47·6%) 50 892 (54·5%)
None 45 (39·8%) 175 (24·5%) 463 (27·0%) 402 (8·6%) 1944 (15·9%) 5100 (16·2%) 8129 (16·0%)
Mild 26 (23·0%) 76 (10·6%) 238 (13·9%) 375 (8·0%) 1081 (8·9%) 3005 (9·6%) 4801 (9·4%)
Advanced 16 (14·2%) 126 (17·7%) 280 (16·3%) 803 (17·1%) 1474 (12·1%) 5303 (16·9%) 8002 (15·7%)
Severe 26 (23·0%) 337 (47·2%) 737 (42·9%) 3113 (66·3%) 7703 (63·1%) 18 044 (57·4%) 29 960 (58·9%)
Known AIDS diagnosis 20 (10·4%) 45 (4·9%) 368 (17·2%) 3526 (57·7%) 9910 (55·5%) 26 392 (39·9%) 40 261 (43·1%)
Weight-for-age Z score† 95 (49·5%) 841 (90·8%) 1051 (49·1%) 5575 (91·3%) 11 610 (65·0%) 49 090 (74·2%) 68 262 (73·1%)
≤–2 19 (20·0%) 368 (43·8%) 168 (16·0%) 3664 (65·7%) 5498 (47·4%) 27 257 (55·5%) 36 974 (54·2%)
>–2 to 0 52 (54·7%) 394 (46·9%) 486 (46·2%) 1644 (29·5%) 4911 (42·3%) 17 785 (36·2%) 25 272 (37·0%)
>0 24 (25·3%) 79 (9·4%) 397 (37·8%) 267 (4·8%) 1201 (10·3%) 4048 (8·3%) 6016 (8·8%)
Initial ART regimen
NNRTI based 114 (59·4%) 827 (89·3%) 1194 (55·7%) 5850 (95·8%) 10 368 (58·1%) 64 532 (97·6%) 82 885 (88·8%)
Nevirapine 85 (44·3%) 277 (29·9%) 680 (31·8%) 4383 (71·8%) 885 (5·0%) 55 354 (83·7%) 61 664 (66·1%)
Efavirenz 28 (14·6%) 550 (59·4%) 514 (24·0%) 1467 (24·0%) 9483 (53·1%) 9178 (13·9%) 21 220 (22·7%)
Other NNRTI 1 (0·5%) 0 0 0 0 0 1 (<0·1%)
Protease inhibitor based 78 (40·6%) 99 (10·7%) 948 (44·3%) 257 (4·2%) 7489 (41·9%) 1595 (2·4%) 10 466 (11·2%)
Ritonavir-boosted lopinavir 66 (34·4%) 94 (10·2%) 895 (41·8%) 253 (4·1%) 7486 (41·9%) 1595 (2·4%) 10 389 (11·1%)
Other protease inhibitor 12 (6·3%) 5 (0·5%) 53 (2·5%) 4 (0·1%) 3 (<0·1%) 0 77 (0·1%)
Calendar year of ART initiation
≤2004 152 (79·2%) 321 (34·7%) 643 (30·0%) 535 (8·8%) 1600 (9·0%) 1448 (2·2%) 4699 (5·0%)
2005–07 28 (14·6%) 207 (22·4%) 529 (24·7%) 1733 (28·4%) 5071 (28·4%) 15 639 (23·7%) 23 207 (24·9%)
2008–10 8 (4·2%) 218 (23·5%) 630 (29·4%) 1891 (31·0%) 7440 (41·7%) 26 433 (40·0%) 36 620 (39·2%)
≥2011 4 (2·1%) 180 (19·4%) 340 (15·9%) 1948 (31·9%) 3746 (21·0%) 22 607 (34·2%) 28 825 (30·9%)
Monitoring strategy
Routine CD4 and viral load 192 (100%) 402 (43·4%) 2123 (99·1%) 3404 (55·7%) 17 857 (100%) 2005 (3·0%) 25 983 (27·8%)
Routine CD4 and targeted viral load 0 0 19 (0·9%) 2442 (40·0%) 0 14 246 (21·5%) 16 707 (17·9%)
Routine CD4 only 0 524 (56·6%) 0 260 (4·3%) 0 35 748 (54·1%) 36 532 (39·1%)
Clinical only 0 0 0 1 (<0·1%) 0 14 128 (21·4%) 14 129 (15·1%)
Country-income group
Low NA 524 (56·6%) NA 2947 (48·3%) NA 36 780 (55·6%) 40 251 (43·1%)
Lower-middle NA 169 (18·3%) 390 (18·2%) 507 (8·3%) NA 29 347 (44·4%) 30 413 (32·6%)
High and upper-middle 192 (100%) 233 (25·2%) 1752 (81·8%) 2653 (43·4%) 17 857 (100%) 0 22 687 (24·3%)
Data are n (%) or median (IQR), unless otherwise indicated. ART=antiretroviral therapy. NA=not applicable. NNRTI=non-nucleoside reverse-transcriptase inhibitor. *CD4% is reported in children younger than 5 years 
and CD4 count is reported for children 5 years and older. The denominators for calculations of the proportion with a measurement are therefore in the subgroups younger than 5 years and aged 5 years and older. †CD4 
data and bodyweight data only recorded in a subset of cohorts, and so the total number of participants, used as the denominator for the proportion calculation in each subcategory, for each region is supplied. The WHO 
immunosuppression-for-age measure uses all data available, both CD4% and CD4 cell count. Here we only report the median CD4% among those younger than 5 years and the median CD4 count in those aged 5 years 
or older, but many patients had both markers recorded.
Table 1: Patient characteristics at time of ART initiation
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from 1993 to 2015, with over 70% of children initiating 
ART in 2008 or later (table 1). Half of patients were male, 
and the median age at ART initiation was 3·9 years 
(IQR 1·6–6·9), with two-thirds aged 5 years or younger. 
The median age at ART initiation was similar across all 
regions, except for in the USA where the median age was 
younger than 1 year. 40 261 (43·1%) children had known 
AIDS diagnosis at ART initiation, and among 
50 892 (54·5%) children with available CD4 data, 
37 962 (74·6%) had advanced or severe immuno deficiency, 
with Asia and southern Africa having the highest 
proportions of patients with severe immuno deficiency.
82 885 (88·8%) children initiated an NNRTI-based 
regimen (61 664 [66·1%] on nevirapine), although 
regional variations were observed (table 1; appendix p 21). 
In southern Africa, 6803 (84%) of 8082 patients younger 
than 3 years at ART initiation were initiated on a 
ritonavir-boosted lopinavir-based regimen compared 
with 1262 (4·5%) of 27 856 in the rest of sub-Saharan 
Africa (appendix p 22).
Strategies for treatment monitoring also varied 
between the geographical regions. In the USA, Europe, 
and southern Africa, almost all patients were in cohorts 
with routine monitoring of CD4 and viral load, whereas 
in Asia 56% of patients were in cohorts with routine 
monitoring of CD4 and viral load and 40% were in 
cohorts with routine monitoring of CD4 and targeted 
monitoring of viral load. In the rest of sub-Saharan 
Africa, only 3·0% of patients were in cohorts with routine 
monitoring of CD4 and viral load, equal proportions of 
patients (21·4%) were in cohorts with routine monitoring 
of CD4 and targeted monitoring of viral load and in 
cohorts with clinical monitoring only, and 54·1% were in 
cohorts with only CD4 monitoring.
Median duration of follow-up after ART initiation was 
26 months (IQR 9–52), with longer follow-up in regions 
outside of Africa (table 2). At data cutoff (without use of 
competing risks and ignoring switching to second-line 
ART) 5417 (5·8%) patients had died, 13 846 (14·8%) 
were lost to follow-up and not known to have died, 
19 888 (21·3%) had transferred to another clinic or to 
adult care, and 54 200 (58·1%) were still in follow-up.
Over 265 942 person-years of follow-up, 4·2% of 
patients met our definition of switching to second-line 
ART, and on the basis of our competing-risk analysis 
0·5% died, 19·6% were lost to follow-up, and 20·7% 
transferred before switching. The crude rate of switching 
was 14·6 switches per 1000 person-years (95% CI 
14·1–15·1). The cumulative incidence of switching by 3 years 
after initiation of ART was 3·1% (95% CI 3·0–3·2), with 
wide variation between geographical region, initial 
regimen, and monitoring strategies (table 2, figure 2A). 
The cumulative incidences of switching by 1, 2, and 
3 years after initiation of ART stratified by these variables 
USA 
(n=192)
Latin America 
(n=926)
Europe 
(n=2142)
Asia 
(n=6107)
Southern Africa 
(n=17 857)
Rest of sub-Saharan 
Africa (n=66 127)
Overall 
(n=93 351)
Follow-up*
Median (IQR), months 41 (23–79) 52 (24–93) 49 (23–81) 38 (17–69) 29 (12–58) 24 (8–47) 26 (9–52)
Switched to second-line ART 72 (37·5%) 123 (13·3%) 464 (21·7%) 587 (9·6%) 1255 (7·0%) 1382 (2·1%) 3883 (4·2%)
Died 0 4 (0·4%) 3 (0·1%) 31 (0·5%) 17 (0·1%) 394 (0·6%) 449 (0·5%)
Lost to follow-up 15 (7·8%) 214 (23·1%) 235 (11·0%) 674 (11·0%) 3446 (19·3%) 13 688 (20·7%) 18 272 (19·6%)
Administrative censoring 105 (54·7%) 585 (63·2%) 1440 (67·2%) 4815 (78·8%) 13 139 (73·6%) 50 663 (76·6%) 70 747 (75·8%)
Cumulative incidence switched by 3 years after start of ART
Overall 26·1% (20·0–32·7) 6·5% (4·9–8·3) 12·2% (10·8–13·7) 6·6% (5·9–7·3) 5·4% (5·1–5·9) 1·5% (1·4–1·6) 3·1% (3·0–3·2)
Age at initiation of ART, years
<3 years 25·7% (18·5–33·4) 4·9% (2·9–7·6) 11·7% (9·8–13·9) 7·0% (5·8–8·3) 3·7% (3·2–4·2) 1·1% (0·9–1·2) 2·5% (2·3–2·7)
3–5 27·6% (13·7–43·3) 5·0% (2·7–8·5) 8·9% (6·4–12·0) 7·0% (5·8–8·4) 6·5% (5·7–7·4) 1·4% (1·2–1·6) 3·1% (2·9–3·4)
6–9 27·1% (9·8–48·0) 8·3% (5·1–12·4) 14·8% (11·5–18·4) 5·6% (4·5–6·9) 7·2% (6·3–8·1) 2·0% (1·8–2·3) 3·7% (3·4–4·0)
≥10 ·· 12·3% (5·7–21·6) 16·6% (11·5–22·5) 6·7% (2·7–13·5) 6·7% (4·5–9·5) 2·4% (1·7–3·4) 4·9% (4·0–5·9)
Initial ART regimen
Protease inhibitor based 10·1% (4·4–18·5) 5·1% (1·6–11·6) 7·0% (5·4–8·8) 3·6% (1·6–7·1) 3·2% (2·7–3·7) 4·3% (3·2–5·7) 3·9% (3·4–4·3)
NNRTI based 37·0% (28·1–45·9) 6·6% (5·0–8·5) 16·1% (14·0–18·4) 6·6% (5·9–7·4) 7·0% (6·4–7·6) 1·4% (1·3–1·5) 3·0% (2·9–3·2)
Monitoring strategy
Routine CD4 and viral load 26·1% (20·0–32·7) 7·7% (5·3–10·7) 12·3% (10·8–13·8) 8·7% (7·8–9·8) 5·4% (5·1–5·9) 6·1% (5·0–7·4) 6·8% (6·5–7·2)
Routine CD4 and targeted 
viral load 
·· ·· 5·9% (0·4–23·5) 2·8% (2·0–3·7) ·· 2·1% (1·8–2·4) 2·2% (1·9–2·4)
Routine CD4 only ·· 5·5% (3·6–7·9) ·· 3·5% (1·1–8·3) ·· 1·1% (1·0–1·3) 1·2% (1·1–1·4)
Clinical only ·· ·· ·· ·· ·· 0·8% (0·6–1·0) 0·8% (0·6–1·0)
Data are n (%) or cumulative incidence (95% CI), unless otherwise indicated. ART=antiretroviral therapy. NNRTI=non-nucleoside reverse-transcriptase inhibitor. *Competing risk analysis, censored at the first of 
the following events: switched to second-line, death, loss to follow-up or date of last clinic visit (before transfer out or data cutoff). 
Table 2: Follow-up status and cumulative incidence of switch by 3 years after start of ART by geographical region
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are shown in the appendix (pp 14–15). We found the 
highest incidence of switching to be among children who 
initiated ART on NNRTI-based regimens in the USA and 
the lowest incidence among children on NNRTI-based 
regimens in sub-Saharan Africa with CD4 or clinical only 
monitoring. Among children who started ART in 2011 or 
later, similar variations in the incidence of switching 
across treatment monitoring strategies was observed 
(appendix p 15). Because the rest of sub-Saharan Africa 
was the only region that used all four types of monitoring 
strategy, we further explored the cumulative incidence of 
switching within this region (figure 2B) and found the 
cumulative incidence of switching at 3 years to be 6·1% 
(95% CI 5·0–7·4) in cohorts with routine monitoring of 
CD4 and viral load compared with less than 2% (table 2) 
in cohorts with no viral load monitoring.
Among the 3883 children who switched to second-line 
ART, the median time to switch was 35 months 
(IQR 20–57; appendix pp 18–19). The median age at switch 
was 8·6 years (IQR 5·5–11·5), and 3329 (85·7%) switches 
were from an NNRTI-based to a protease inhibitor-based 
regimen, 419 (10·8%) were from a protease inhibitor-
based to an NNRTI-based regimen, and 135 (3·5%) were 
other switches. Among children with recorded CD4% or 
CD4 cell counts at the time of switch (n=3016), 
1265 (41·9%) had severe immunodeficiency and 
359 (11·9%) had advanced immunodeficiency. Among the 
2419 (62·3%) patients with measurements of viral load at 
the time of switching, 2013 (83·2%) had a viral load of 
more than 1000 copies per mL. 203 (5%) patients had a 
tuberculosis diagnosis at the time of switching. 75 children 
younger than 3 years at the start of lopinavir-based first-
line ART switched to an NNRTI-based second-line ART 
when older than 3 years and while virally suppressed to 
under 1000 copies per mL. Among the 2219 (57%) patients 
with a reported reason for switching, 1132 (51%) switched 
because of treatment failure, 67 (3%) because of toxic side-
effects of drugs, and 1020 (46%) because of other 
(unspecified) reasons.
In our multivariable analyses, individual patient-level 
factors associated with an increased likelihood of 
switching were male sex, older age at ART initiation, 
initiation of ART on an NNRTI-based regimen, and earlier 
calendar year of initiation of ART (table 3). In the 
multivariable analysis of cohort-level factors associated 
with switching, treatment monitoring strategy was 
indentified as a factor. Compared with monitoring of CD4 
only, routine CD4 and viral load monitoring was associated 
with a 166% increase in the likelihood of switching, 
whereas clinical only monitoring was associated with 
a 32% decrease in likelihood (table 3). High-income and 
upper-middle-income countries were associated with an 
increased likelihood of switching compared with low-
income countries. All geographical regions outside of 
Africa had increased likelihoods of switching compared 
with southern Africa, whereas we saw no difference 
between southern Africa and the rest of sub-Saharan Africa.
In the first sensitivity analysis, which was restricted to 
patient-level data from a subset of cohorts that recorded 
CD4% or CD4 cell count and bodyweight at ART 
initiation in over 60% of participants (n=39 724), the risk 
factors for switching remained consistent with the main 
analyses, except for some differences in the effect of 
the geo graphical region. Patients in the rest of 
sub-Saharan Africa had a decreased likelihood of 
switching compared with those in southern Africa. The 
association between country-level incomes was no longer 
present (table 3). Additionally, patients with severe 
immuno deficiency had an increased likelihood 
Figure 2: Cumulative incidence of switching to second-line ART among children at 3 years after ART initiation
(A) Incidence by region. (B) Incidence by monitoring strategy for sub-Saharan Africa (excluding Botswana and 
South Africa) only at 3 years after ART initiation. ART=antiretroviral therapy. 
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All children (main analysis; n=93 351) Subset of cohorts that recorded CD4% or CD4 cell count and 
bodyweight at ART initiation (sensitivity analyses; n=39 724)
Univariable analysis Multivariable 
analysis
Univariable analysis Multivariable analysis, 
not including immuno-
deficiency for age and 
weight-for-age Z score
Multivariable analysis, 
including immuno-
deficiency for age and 
weight-for-age Z score
Patient-level factors 
Sex p<0·0001 p<0·0001 p<0·0001 p<0·0001 p<0·0001
Female vs male 0·79 (0·74–0·84) 0·78 (0·73–0·83) 0·80 (0·75–0·86) 0·79 (0·74–0·84) 0·81 (0·74–0·88)
Age, years p<0·0001 p<0·0001 p<0·0001 p<0·0001 p<0·0001
<3 0·61 (0·56–0·66) 0·63 (0·58–0·68) 0·58 (0·54–0·63) 0·68 (0·62–0·74) 0·62 (0·54–0·70)
3–5 0·77 (0·71–0·84) 0·73 (0·67–0·79) 0·78 (0·71–0·85) 0·75 (0·69–0·82) 0·71 (0·64–0·79)
6–9 1 1 1 1 1
≥10 1·24 (1·11–1·51) 1·15 (0·98–1·35) 1·17 (1·00–1·37) 1·17 (0·99–1·38) 1·26 (1·05–1·51)
Known AIDS diagnosis p=0·16 p=0·10 p=0·16 p=0·87 p=0·96
Yes vs no 0·96 (0·90–1·02) 0·95 (0·88–1·01) 1·05 (0·98–1·12) 1·01 (0·94–1·08) 1·00 (0·88–1·16)
Immunodeficiency for age ·· ·· p<0·0001 ·· p<0·0001
None ·· ·· 1·07 (0·90–1·27) ·· 0·91 (0·75–1·10)
Mild ·· ·· 1·21 (1·00–1·46) ·· 1·16 (0·85–1·43)
Advanced ·· ·· 1 ·· 1
Severe ·· ·· 1·39 (1·21–1·58) ·· 1·40 (1·21–1·62)
Weight-for-age Z score ·· ·· p=0·38 ·· p=0·17
≤–2 ·· ·· 0·95 (0·87–1·03) ·· 1·07 (0·97–1·17)
>–2 to 0 ·· ·· 1 ·· 1
>0 ·· ·· 1·00 (0·87–1·16) ·· 0·93 (0·80–1·09)
Initial ART regimen p=0·004 p<0·0001 p<0·0001 p<0·0001 p<0·0001
Protease inhibitor based vs 
NNRTI based
1·15 (1·05–1·26) 0·70 (0·63–0·79) 0·68 (0·61–0·76) 0·51 (0·45–0·58) 0·58 (0·49–0·68)
Calendar year p<0·0001 p<0·0001 p<0·0001 p<0·0001 p<0·0001
≤2004 2·96 (2·70–3·24) 1·39 (1·26–1·53) 2·28 (2·08–2·51) 1·41 (1·27–1·56) 1·41 (1·24–1·61)
2005–07 1·45 (1·35–1·57) 1·26 (1·17–1·36) 1·27 (1·17–1·38) 1·18 (1·08–1·28) 1·18 (1·07–1·30)
2008–10 1 1 1 1 1
≥2011 0·55 (0·47–0·63) 0·61 (0·53–0·71) 0·49 (0·41–0·58) 0·53 (0·44–0·62) 0·59 (0·48–0·73)
Cohort–level factors
Cohort monitoring strategy p<0·0001 p<0·0001 p<0·0001 p<0·0001 p<0·0001
Routine CD4 and viral load 4·57 (4·18–5·00) 2·66 (2·22–3·19) 2·81 (2·55–3·10) 1·90 (1·60–2·26) 2·37 (1·94–2·89)
Routine CD4 and targeted viral 
load
2·18 (1·95–2·43) 1·95 (1·75–2·18) 1·29 (1·15–1·45) 1·29 (1·13–1·46) 1·43 (1·24–1·66)
Routine CD4 only 1 1 1 1 1
Clinical only 0·75 (0·62–0·91) 0·68 (0·56–0·83) ·· ·· ··
Country-income group p<0·0001 p=0·0017 p<0·0001 p=0·22 p=0·44
Low 1 1 1 1 1
Lower-middle 1·04 (0·94–1·14) 1·09 (0·98–1·21) 1·01 (0·90–1·12) 1·09 (0·96–1·20) 1·01 (0·88–1·16)
High and upper-middle 3·21 (2·98–3·47) 1·33 (1·13–1·56) 2·26 (2·09–2·46) 1·14 (0·97–1·33) 0·87 (0·71–1·08)
Geographical region p<0·0001 p<0·0001 p<0·0001 p<0·0001 p<0·0001
USA 4·16 (3·20–5·42) 4·04 (3·07–5·32) 3·01 (1·84–4·93) 2·73 (1·63–4·58) 4·39 (2·28–8·46)
Europe 2·30 (2·07–2·56) 2·22 (1·97–2·49) 2·05 (1·83–2·29) 1·84 (1·63–2·09) 2·22 (1·87–2·63)
Latin America 1·23 (1·03–1·49) 1·73 (1·40–2·15) 1·28 (1·05–1·55) 1·59 (1·27–2·00) 1·88 (1·46–2·42)
Asia 1·27 (1·15–1·40) 1·38 (1·23–1·54) 1·18 (1·07–1·31) 1·06 (0·94–1·18) 0·86 (0·74–1·01)
Southern Africa 1 1 1 1 1
Rest of sub-Saharan Africa 0·35 (0·33–0·38) 0·89 (0·74–1·07) 0·47 (0·44–0·52) 0·69 (0·57–0·83) 0·66 (0·52–0·84)
Data are subdistributional hazard ratios (95% CIs) unless otherwise stated. CD4 means CD4% or CD4 cell count. ART=antiretroviral therapy. NNRTI=non-nucleoside reverse 
transcriptase inhibitor.
Table 3: Factors associated with switching to second-line ART
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of switching compared with those with advanced 
immuno deficiency, but we saw no association between 
switching and weight-for-age Z score at initiation of ART.
In the second sensitivity analysis that broadened the 
definition of switching, the number of patients who met 
the definition increased from 3883 (4·2%) to 4035 (4·3%). 
Most of the additional switches were from an NNRTI-
based to a protease inhibitor-based regimen. Factors 
associated with switching and hazard estimates were 
broadly similar to those identified in the main analyses 
(appendix pp 16–17).
Discussion
The incidence of switching to second-line ART among 
children with HIV≠≠ was 14·6 switches per 
1000 person-years with a cumulative incidence of 3·1% by 
3 years after initiation of ART. However, we identified 
large variations between individual patient characteristics, 
geographical regions, and by cohort monitoring strategies.
3 years after initiation of ART, the cumulative 
incidence of switching was lowest among patients in 
cohorts in the rest of sub-Saharan Africa with clinical 
only monitoring, and was only slightly increased in this 
region when monitoring of CD4 was available. These 
estimates are lower than the median proportion of 
patients who switched after 4 years of follow-up reported 
in the ARROW trial (63 [5%] of 1206),7 which was 
conducted in the rest of sub-Saharan Africa where all 
patients initiated NNRTI-based regimens and were 
managed with only clinical or CD4 monitoring. 
However,  because ARROW is a clinical trial, patients 
were followed up more closely than they might be in 
routine care, and the median duration of follow-up in 
ARROW (4 years [IQR 3·7–4·4]) was longer than in our 
cohort. WHO forecasting models estimate that the 
proportion of children with HIV on ART globally who 
are receiving second-line regimens, irrespective of 
duration on ART, was 4·1% in 2013 and increased to 
6·1% in 2015.22 However, these estimates are cross-
sectional and based on extrapolations from historical 
trends in global antiretroviral procurement data and 
projections from assumptions regarding ART coverage. 
Therefore, the estimates cannot be directly compared 
with our estimates of cumulative incidence of switching 
to second-line ART at 3 years after initiation of ART.
In our analysis, patients who were managed in settings 
that monitored their viral load were twice as likely to 
switch to second-line ART compared with children in 
settings that only had access to CD4 or clinical monitoring, 
or both. This finding is consistent with findings from 
adult HIV modelling studies23 that estimate that the 
number of patients receiving second-line ART in settings 
with rapid scale-up of viral load monitoring will increase 
two to three times compared with slow or no scale-up of 
viral load monitoring.
Studies24,25 have reported that 20–40% of children with 
only clinical or CD4 monitoring had evidence 
of virological failure (viral load ≥1000 copies per mL) at 
3–4 years after initiation of ART, highlighting the poor 
sensitivity of these monitoring strategies in detecting 
virological failure. This issue is particularly important 
in sub-Saharan Africa where most children initiate ART 
on NNRTI-based regimens with low genetic thresholds 
for resistance.26 Although the PENPACT-1 trial9 reported 
no difference in clinical outcomes of children on 
NNRTI-based or protease inhibitor-based regimens who 
were assigned to switch to second-line ART after 
virological failure at over 1000 copies per mL (early 
switch) or at over 10 000 copies per mL (delayed switch), 
adult studies27,28 in sub-Saharan Africa have shown 
increased risks of morbidity and mortality in patients 
with delayed switching to second-line ART. A 
comparison of the clinical outcomes of children 
managed under a variety of monitoring strategies and 
time between treat ment failure and switching is 
warranted to determine the best use of resources to 
obtain optimal outcomes in this population.
In our study, we estimated that most regions had a 
higher cumulative incidence of switching to second-line 
ART among children who initiated an NNRTI-based 
regimen than among those who initiated a protease 
inhibitor-based regimen. However, in the rest of 
sub-Saharan Africa we estimated a higher cumulative 
incidence of switching among children who initiated 
protease inhibitor-based regimens than those who 
initiated NNRTI-based regimens, although this estimate 
was based on a small proportion of children starting on 
protease inhibitors in that region (2·4%, all ritonavir-
boosted lopinavir). Review of these data indicates that 
our finding might be partly because of incident 
tuberculosis and the need to avoid protease inhibitors 
when initiating a tuberculosis treatment regimen 
containing rifampin. Because the tuberculosis data were 
incompletely reported, we could not completely explore 
this hypothesis. The finding that older age at initiation of 
ART is associated with an increased likelihood of 
switching has been previously reported11,13 and could be 
partly due to the lack of available paediatric formulations 
for young children and poorer adherence among 
adolescents than among younger children. The increased 
incidence of switching among male patients has been 
previously reported in paediatric and adult cohorts,11,12,29 
and warrents further study.
Our analysis suggested that even after adjusting for 
monitoring strategy and patient-level characteristics, 
being in the rest of sub-Saharan Africa and in low-income 
countries remained independently associated with a 
decreased likelihood of switching to second-line therapy. 
The comparatively less frequent use of second-line ART 
in such settings, even when viral load monitoring was 
available, could partly be because of the higher thresholds 
for virological failure recommended by WHO for low-
income and middle-income countries than for high-
income and upper-middle-income countries.30 This 
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finding could also reflect the paucity of access to second-
line drugs and clinicians’ fears about availability of 
subsequent third-line therapy, although these factors 
were not measured in our study.
The low global cumulative incidence of switching to 
second-line ART reported in our analysis, which was 
dominated by a large number of children in southern 
Africa and the rest of sub-Saharan Africa, reflects 
standard practice for those who intitated ART between 
1993 and 2015 in participating programmes. Since 2015, 
scale-up of viral load monitoring has been ongoing and 
is likely to substantially increase the early detection of 
treatment failure and demand for second-line ART. 
However, the extent of the increase in demand for second-
line ART across settings remains unclear and will still be 
subject to local resources and guidance. Although less 
guidence and data exist on the optimal use of the low-cost 
integrase inhibitor dolutegravir in second-line ART in 
children, its roll-out as first-line and second-line ART in 
adults will probably lead to increased call for its use in 
children.31 Because our study spans a large age spectrum 
and time period, it provides crucial insight into how 
clinicians have assessed and responded to first-line 
treatment failure in children on ART to date. These 
insights can be of use both to forecast future paediatric 
ART needs and to identify settings in which the system 
might be failing children and potential points of 
intervention. Future assessments of the durability of 
first-line regimens in-line with when new drugs are rolled 
out will be crucial to ensure sufficient availability of 
paediatric formulations in the future.
This study had several limitations. First, few cohorts 
reported data on the reasons for ART switch, and among 
those that did report reasons almost half of the reasons 
were unspecified as other reasons. Furthermore, few 
cohorts had data on viral load at the time of switching, 
and so we could not elucidate whether the switch was 
because of treatment failure. However, because of our 
conservative definition of switching to second-line ART, 
we feel that most of the switches were true switches to 
second-line ART rather than minor treatment modifi-
cations or simplifications. Since 2010 in South Africa, 
guidelines have recommended to switch children aged 
3 years and older to an NNRTI-based regimen if they 
were younger than 3 years at initiation of a lopinavir-
based ART regimen and if they were virally suppressed.14 
We considered that this recommendation might lead to 
overestimation of switches among this population; 
however, only 75 children were switched in this manner 
while virally suppressed, and thus their potential 
misclassification would not substantially affect our 
findings. Second, this is an observational study with 
sources of potential bias such as the high proportion of 
children lost to follow-up, which has probably resulted 
in incomplete ascertainment of switching and deaths. 
This limitation has been addressed in part by our use of 
a competing-risk analyses. Third, AIDS diagnoses 
might have been under-reported at initiation of ART in 
some low-income country settings because of restricted 
capacity for clinical diagnostics. Data are also incomplete 
on co-infections (eg, tuberculosis) and the availability of 
alternative antiretroviral drugs restricted our ability to 
explore possible reasons for the geographical variations 
in switching patterns. Finally, although this is a large 
global cohort collaboration, we are still extrapolating 
data from a finite number of cohorts to a global estimate.
In conclusion, we found that the cumulative incidence 
of switching to second-line ART varied widely between 
both geographical regions and by monitoring strategies. 
Given the maturing cohorts and expanding roll-out of 
viral load testing and new drugs, we anticipate that the 
use of second-line regimens will increase, although 
geographical variation will most likely persist for the 
foreseeable future. The effect of delayed versus fast 
switching to second-line ART after treatment failure on 
longer-term clinical outcomes and treatment options 
among children remain unclear and warrant further 
exploration.
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